97 related articles for article (PubMed ID: 25119583)
1. Blockade of epidermal growth factor receptor/mammalian target of rapamycin pathway by Icariside II results in reduced cell proliferation of osteosarcoma cells.
Geng YD; Yang L; Zhang C; Kong LY
Food Chem Toxicol; 2014 Nov; 73():7-16. PubMed ID: 25119583
[TBL] [Abstract][Full Text] [Related]
2. Icariside II, a natural mTOR inhibitor, disrupts aberrant energy homeostasis via suppressing mTORC1-4E-BP1 axis in sarcoma cells.
Zhang C; Yang L; Geng YD; An FL; Xia YZ; Guo C; Luo JG; Zhang LY; Guo QL; Kong LY
Oncotarget; 2016 May; 7(19):27819-37. PubMed ID: 27056897
[TBL] [Abstract][Full Text] [Related]
3. Icariside II induces apoptosis via inhibition of the EGFR pathways in A431 human epidermoid carcinoma cells.
Wu J; Zuo F; Du J; Wong PF; Qin H; Xu J
Mol Med Rep; 2013 Aug; 8(2):597-602. PubMed ID: 23807305
[TBL] [Abstract][Full Text] [Related]
4. Chrysophanic acid blocks proliferation of colon cancer cells by inhibiting EGFR/mTOR pathway.
Lee MS; Cha EY; Sul JY; Song IS; Kim JY
Phytother Res; 2011 Jun; 25(6):833-7. PubMed ID: 21089180
[TBL] [Abstract][Full Text] [Related]
5. Icariside II activates EGFR-Akt-Nrf2 signaling and protects osteoblasts from dexamethasone.
Liu W; Mao L; Ji F; Chen F; Wang S; Xie Y
Oncotarget; 2017 Jan; 8(2):2594-2603. PubMed ID: 27911877
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of mTOR signaling by oleanolic acid contributes to its anti-tumor activity in osteosarcoma cells.
Zhou R; Zhang Z; Zhao L; Jia C; Xu S; Mai Q; Lu M; Huang M; Wang L; Wang X; Jin D; Bai X
J Orthop Res; 2011 Jun; 29(6):846-52. PubMed ID: 21246613
[TBL] [Abstract][Full Text] [Related]
7. Physakengose G induces apoptosis via EGFR/mTOR signaling and inhibits autophagic flux in human osteosarcoma cells.
Lin H; Zhang C; Zhang H; Xia YZ; Zhang CY; Luo J; Yang L; Kong LY
Phytomedicine; 2018 Mar; 42():190-198. PubMed ID: 29655686
[TBL] [Abstract][Full Text] [Related]
8. Icariside II from Epimedium koreanum inhibits hypoxia-inducible factor-1alpha in human osteosarcoma cells.
Choi HJ; Eun JS; Kim DK; Li RH; Shin TY; Park H; Cho NP; Soh Y
Eur J Pharmacol; 2008 Jan; 579(1-3):58-65. PubMed ID: 17980359
[TBL] [Abstract][Full Text] [Related]
9. Epidermal growth factor-induced cell death and radiosensitization in epidermal growth factor receptor-overexpressing cancer cell lines.
Kim K; Wu HG; Jeon SR
Anticancer Res; 2015 Jan; 35(1):245-53. PubMed ID: 25550557
[TBL] [Abstract][Full Text] [Related]
10. Janus activated kinase 2/signal transducer and activator of transcription 3 pathway mediates icariside II-induced apoptosis in U266 multiple myeloma cells.
Kim SH; Ahn KS; Jeong SJ; Kwon TR; Jung JH; Yun SM; Han I; Lee SG; Kim DK; Kang M; Chen CY; Lee JW; Kim SH
Eur J Pharmacol; 2011 Mar; 654(1):10-6. PubMed ID: 21172343
[TBL] [Abstract][Full Text] [Related]
11. Rapamycin inhibits tumor growth of human osteosarcomas.
Zhao S; Lu N; Chai Y; Yu X
J BUON; 2015; 20(2):588-94. PubMed ID: 26011354
[TBL] [Abstract][Full Text] [Related]
12. [Inhibitory effect and significance of rapamycin on the mammalian target of rapamycin signaling pathway in osteosarcoma stem cells and osteosarcoma cells].
Liu PY; Zhang WB; Wang J; Shen YH; Wei YY
Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):175-80. PubMed ID: 23879996
[TBL] [Abstract][Full Text] [Related]
13. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
Gadgeel SM; Wozniak A
Clin Lung Cancer; 2013 Jul; 14(4):322-32. PubMed ID: 23332287
[TBL] [Abstract][Full Text] [Related]
14. Combined inhibition of the EGFR and mTOR pathways in EGFR wild-type non-small cell lung cancer cell lines with different genetic backgrounds.
Huang Y; Chen Y; Mei Q; Chen Y; Yu S; Xia S
Oncol Rep; 2013 Jun; 29(6):2486-92. PubMed ID: 23525575
[TBL] [Abstract][Full Text] [Related]
15. Paradigm of kinase-driven pathway downstream of epidermal growth factor receptor/Akt in human lung carcinomas.
Dobashi Y; Suzuki S; Kimura M; Matsubara H; Tsubochi H; Imoto I; Ooi A
Hum Pathol; 2011 Feb; 42(2):214-26. PubMed ID: 21040950
[TBL] [Abstract][Full Text] [Related]
16. Activation of mammalian target of rapamycin in transformed B lymphocytes is nutrient dependent but independent of Akt, mitogen-activated protein kinase/extracellular signal-regulated kinase kinase, insulin growth factor-I, and serum.
Wlodarski P; Kasprzycka M; Liu X; Marzec M; Robertson ES; Slupianek A; Wasik MA
Cancer Res; 2005 Sep; 65(17):7800-8. PubMed ID: 16140948
[TBL] [Abstract][Full Text] [Related]
17. Synergistic effects of erlotinib and everolimus on bronchial carcinoids and large-cell neuroendocrine carcinomas with activated EGFR/AKT/mTOR pathway.
Bago-Horvath Z; Sieghart W; Grusch M; Lackner A; Hayden H; Pirker C; Komina O; Węsierska-Gądek J; Haitel A; Filipits M; Berger W; Schmid K
Neuroendocrinology; 2012; 96(3):228-37. PubMed ID: 22378048
[TBL] [Abstract][Full Text] [Related]
18. Transforming growth factor alpha promotes osteosarcoma metastasis by ICAM-1 and PI3K/Akt signaling pathway.
Hou CH; Lin FL; Tong KB; Hou SM; Liu JF
Biochem Pharmacol; 2014 Jun; 89(4):453-63. PubMed ID: 24685520
[TBL] [Abstract][Full Text] [Related]
19. A cross-talk between the androgen receptor and the epidermal growth factor receptor leads to p38MAPK-dependent activation of mTOR and cyclinD1 expression in prostate and lung cancer cells.
Recchia AG; Musti AM; Lanzino M; Panno ML; Turano E; Zumpano R; Belfiore A; Andò S; Maggiolini M
Int J Biochem Cell Biol; 2009 Mar; 41(3):603-14. PubMed ID: 18692155
[TBL] [Abstract][Full Text] [Related]
20. EGF receptor transactivation mediates ANG II-stimulated mitogenesis in intestinal epithelial cells through the PI3-kinase/Akt/mTOR/p70S6K1 signaling pathway.
Chiu T; Santiskulvong C; Rozengurt E
Am J Physiol Gastrointest Liver Physiol; 2005 Feb; 288(2):G182-94. PubMed ID: 15358595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
